Small-Molecule Switches Enable On-Demand Control of CRISPR Gene Editing for Therapeutic Applications

In a significant leap forward for gene editing technology, a team of researchers led by Dr. Wang Yu from the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences has unveiled two groundbreaking systems: PRINCE and Little Prince. Published in Science Translational Medicine, these dual small-molecule-controlled genome editing platforms are designed to revolutionize therapeutic CRISPR applications by allowing precise, on-demand activation and deactivation of gene editing activity using drug inducers, keeping the systems largely silent in their absence. Current therapeutic CRISPR strategies often rely on a passive approach, where RNA or protein editors are delivered, act for a limited time, and then gradually degrade. Dr. Wang Yu highlighted the critical limitation of this method, stating, "Natural decay is not the same as active control." The team’s objective was to transcend this passive control, aiming to make genome editing not only highly efficient but also precisely controllable in time. PRINCE achieves this through a sophisticated dual-layer regulatory mechanism, coordinating a small-molecule-responsive nuclear localization module for the nuclease protein and a doxycycline-responsive system for guide RNA expression. This innovative dual control significantly reduces unwanted background editing while ensuring potent and efficient editing upon induction. The efficacy of PRINCE was rigorously tested in human cells, demonstrating stringent control even after stable genomic integration and two years of continuous culture. A brief 24-hour exposure to drug inducers efficiently activated editing, whereas uninduced cells exhibited minimal background activity. Furthermore, whole-genome analyses revealed substantially less off-target activity compared to constitutive CRISPR systems, a crucial factor for therapeutic safety. The researchers successfully extended this control principle to prime editing, showcasing its versatility. To facilitate in vivo and particularly in situ delivery, the team developed Little Prince, a compact version based on miniature nucleases that can be packaged into a single adeno-associated virus (AAV) vector. The name "Little Prince," inspired by Antoine de Saint-Exupéry's classic novel, reflects the researchers' hope that these safer and more controllable genome editing technologies will become a meaningful gift for patients, especially children suffering from rare diseases. The therapeutic potential of Little Prince was validated in humanized mouse models. In a model of hypercholesterolemia, AAV8-delivered Little Prince effectively targeted human PCSK9 in the liver. Drug induction led to robust in situ editing, resulting in a remarkable reduction of serum total cholesterol and low-density lipoprotein (LDL) cholesterol by roughly half. Collaborating with Fudan University, the researchers also tested Little Prince in a humanized mouse model of neovascular age-related macular degeneration, targeting human VEGFA in the retina. This application successfully reduced pathological vascular leakage and lesion size, concurrently improving retinal function. This pioneering work introduces a much-needed "start" and "stop" button for gene editing, leveraging small molecules as a safety harness to actively control the editing process. While PRINCE and Little Prince provide compelling proof of concept for pharmacologically controlled genome editing directly in native tissues, further studies are essential to comprehensively assess their long-term safety and broader applicability across various therapeutic contexts. This breakthrough marks a pivotal step towards a new era of precise and safe gene therapies.